# Combined Carfilzomib and Hydroxychloroquine in Patients With Relapsed/Refractory Multiple Myeloma

> **NCT04163107** · PHASE1 · COMPLETED · sponsor: **Norwegian University of Science and Technology** · enrollment: 19 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Hydroxychloroquine
- **DRUG:** Carfilzomib Injection
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT04163107
- **Lead sponsor:** Norwegian University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-07
- **Primary completion:** 2021-12-28
- **Final completion:** 2021-12-28
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2022-03-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04163107

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04163107, "Combined Carfilzomib and Hydroxychloroquine in Patients With Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04163107. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*